Black Diamond Therapeutics, Inc.
BDTX
Rank in Stocks
#19431
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to... Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Share Price
$1.86
Last synced: 2026-11-09
Market Cap
$106.58M
Change (1 day)
7.20%
Change (1 year)
-59.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Black Diamond Therapeutics, Inc. (BDTX)
Category
Healthcare
EPS for Black Diamond Therapeutics, Inc. (BDTX)
EPS as of June 2026 TTM: $-0.74
According to Black Diamond Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.74. At the end of 2025 the company had an EPS of $0.39, an increase over its 2024 EPS of $-1.27.
EPS history for Black Diamond Therapeutics, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.74 | -289.74% |
| 2025 | $0.39 | -130.71% |
| 2024 | $-1.27 | -32.45% |
| 2023 | $-1.88 | -25.40% |
| 2022 | $-2.52 | -27.38% |
| 2021 | $-3.47 | 70.10% |
| 2020 | $-2.04 | 77.39% |
| 2019 | $-1.15 | 79.69% |
| 2018 | $-0.64 | 0.00% |
| 2017 | $-0.64 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,216.22% |
US
|
|
| $-7.07 | 855.41% |
US
|
|
| $-5.29 | 614.86% |
AU
|
|
| $12.88 | -1,840.55% |
BE
|
|
| $21.56 | -3,013.51% |
NL
|
Questions about Black Diamond Therapeutics, Inc.'s earnings per share (EPS)
What is Black Diamond Therapeutics, Inc.'s earnings per share (EPS)?
Black Diamond Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.74, as of Jun 2026.
What was Black Diamond Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Black Diamond Therapeutics, Inc.'s earnings per share (EPS) was $0.39, compared with $-1.27 in 2024.
How has Black Diamond Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Black Diamond Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($0.39) and lowest in 2021 ($-3.47).
How does Black Diamond Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Black Diamond Therapeutics, Inc.'s earnings per share (EPS) ($-0.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.